3PC-024 Application of a matrix risk to an appropriate compounding process of aflibercept and ranibizumab intravitreal injections

BACKGROUND: Compounded sterile drugs have to be prepared in appropriate conditions that ensure their safety in order to prevent medication error and avoid patient harm. PURPOSE: To analyse risks associated with preparation of intravitreal injections (aflibercept and ranibizumab) in our Pharmacy Depa...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur J Hosp Pharm
Prif Awduron: Madroñal, IM Carrión, Gómez, E Sánchez, Rey, MB Contreras, Milá, JI Ynfante, Martín, C Bocanegra, Molíns, E Rodríguez
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Group 2018
Pynciau:
Section 3: Production and compounding
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535308/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.76
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg